Merck & Co Inc: (MRK)
(Real Time Quote from BATS)
Trades from
$3
$62.58 USD
+0.43 (0.69%)
Updated Sep 27, 2016 01:42 PM ET
Volume: 3,052,878
Open: $62.31
Prior Close: $62.15
The Zacks Scorecard is a complimentary set of indicators to use alongside the Zacks Rank. It allows the investor to better focus on the stocks that are the best fit for his or her personal investment style.
We produce five unique ratings, including the Zacks Style Score, which combines the individual style scores into 1 rating:
| Zacks Style Score | A |
|---|---|
| Growth Score | A |
| Value Score | A |
| Momentum Score | A |
| Income Score | A |
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a score of an A or a B in your personal trading style.
Zacks Scorecard Education - Learn more about the Zacks Scorecard
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
| Value Score | A |
|---|---|
| Growth Score | A |
| Momentum Score | A |
| VGM Score | A |
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 25.71% |
| 2 | Buy | 18.12% |
| 3 | Hold | 9.91% |
| 4 | Sell | 5.49% |
| 5 | Strong Sell | 2.29% |
| S&P | 500 | 9.79% |
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The way to access to the Zacks Rank
The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.
The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.
The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.
Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.
Industry / Sector Report
Industry: LARGE CAP PHARMA
Zacks Industry Rank: 79 / 265 (Top 29.81%)
Premium Research: Industry Analysis
| Top Peers | Symbol | Zacks Rank |
|---|---|---|
| MERCK & CO INC | MRK |  |
| ABBOTT LABS | ABT | |
| GLAXOSMITHKLINE | GSK | |
| LILLY ELI & CO | LLY | |
| ABBVIE INC | ABBV | |
| ASTRAZENECA PLC | AZN | |
| BAYER A G -ADR | BAYRY | |
| BRISTOL-MYERS | BMY | |
| H LUNDBECK A S | HLUYY | |
| JOHNSON & JOHNS | JNJ | |
Recommendations and Estimates
| Company | Industry | SP500 | |
|---|---|---|---|
| Average Recommendation (1=Buy, 5=Sell) | 2.08 | 2.20 | 9.99 |
| Current Quarter Estimate | 0.98 | 25.90 | 29.50 |
| Year Ago Quarter Estimate | 0.96 | 18.04 | 26.14 |
| Next Quarter Estimate | 0.95 | 24.20 | 30.50 |
| Next Year Estimate | 3.78 | 10.92 | 25.44 |
Growth Rates
| Company | Industry | SP500 | |
|---|---|---|---|
| This Year (4.2) | 4.20 | 5.00 | 19.00 |
| Next Year (.9) | 0.90 | 12.70 | 5.20 |
| Last 5 Years | 0.60 | 0.10 | 4.90 |
| Next 5 Years | 5.70 | 9.60 | NA |
Financials
| Company | Industry | |
|---|---|---|
| Price/Earnings (TTM) | 16.75 | 18.19 |
| Price/Book (MRQ) | 3.96 | 5.21 |
| Price/Cash Flow (MRFY) | 10.48 | 13.38 |
| Dividend Yield | 2.96% | 2.69% |
| Net Profit Margin (TTM) | 13.01% | 13.01% |
| Return on Equity (TTM) | 23.41% | 24.70% |
| Debt to Equity (MRQ) | 0.54 | 32.57 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.